Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 500 Shares

Key Points

• Floyd F. Petersen, Director of Amphastar Pharmaceuticals, sold 500 shares at an average price of $20.83, which decreased his total position by 0.64%.
• The stock's current trading price is $21.40 with a market cap of approximately $1.01 billion, and it has a 52-week high of $53.96.
• Institutional investors hold about 65.09% of the company's shares, indicating strong confidence from financial institutions in Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd F. Petersen sold 500 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $20.83, for a total value of $10,415.00. Following the transaction, the director directly owned 77,031 shares of the company's stock, valued at $1,604,555.73. The trade was a 0.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock traded up $0.19 during mid-day trading on Monday, reaching $21.40. 463,650 shares of the stock were exchanged, compared to its average volume of 476,827. The firm has a 50-day simple moving average of $23.65 and a 200 day simple moving average of $26.53. The company has a market cap of $1.01 billion, a price-to-earnings ratio of 7.75 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $53.96. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Assetmark Inc. raised its position in Amphastar Pharmaceuticals by 8.0% in the second quarter. Assetmark Inc. now owns 43,766 shares of the company's stock worth $1,005,000 after acquiring an additional 3,229 shares during the period. Hantz Financial Services Inc. boosted its position in shares of Amphastar Pharmaceuticals by 3,430.8% during the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company's stock valued at $32,000 after buying an additional 1,338 shares during the last quarter. Arkadios Wealth Advisors increased its holdings in Amphastar Pharmaceuticals by 3.5% during the second quarter. Arkadios Wealth Advisors now owns 35,163 shares of the company's stock valued at $807,000 after buying an additional 1,197 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Amphastar Pharmaceuticals during the second quarter valued at about $407,000. Finally, AlphaQuest LLC raised its stake in Amphastar Pharmaceuticals by 149.1% during the second quarter. AlphaQuest LLC now owns 28,882 shares of the company's stock valued at $663,000 after purchasing an additional 17,289 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.